Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Asude Aksoy, Gokhan Artas, Tuncay Kuloglu, Mustafa Koc
{"title":"Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma.","authors":"Asude Aksoy,&nbsp;Gokhan Artas,&nbsp;Tuncay Kuloglu,&nbsp;Mustafa Koc","doi":"10.14744/nci.2022.49260","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The balance between malignant tumor cells and the connective tissue surrounding them determines the aggressiveness of the tumor. We aimed to understand the effects of mesothelin (MSLN) and fibulin1 (FBLN1) expressions on survival in pancreas ductal adenocarcinoma (PDCA), and also whether these proteins have prognostic value for PDCA.</p><p><strong>Methods: </strong>Of 80 patients in total, 40 who underwent the Whipple procedure for diagnosed PDCA between 2009 and 2016, and 40 patients with diagnosed pancreatitis as the control group, were included in the present study. Immunohistochemically, MSLN, and FBLN1 expressions were evaluated retrospectively. We assessed the relationship between the degree of MSLN, FBLN1 expression, clinical-pathological features, and survival rates in PDCA cases.</p><p><strong>Results: </strong>The median follow-up duration was 11.4 (3-41) months. All of the patients for MSLN and FBLN1 were immune reactive. We detected a significant difference in MSLN expression between patients with PDCA and control groups, but not in FBLN1 expression. MSLN, FBLN1 expressions were categorized as lower-higher (L/H) groupings. There was no difference in the median overall survival (OS) of patients in the MSLN groups. The L-FBLN1 group had a median OS of 18 months (95% CI: 9.51-26.48) versus 14 months (95% CI: 13.021-14.97) in the H-FBLN1 group (interconnective tissue) (p=0.035). According to Kaplan-Meier analysis, L-FBLN1 expression in the tumor microenvironment was associated with longer survival in PDCA. The FBLN1 expression in the tumor microenvironment was shown to be significantly inversely related to OS (p=0.05).</p><p><strong>Conclusion: </strong>The FBLN1 expression, which is in the tumor microenvironment of PDCA, may serve as a prognostic biomarker.</p>","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/7f/NCI-10-314.PMC10331239.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2022.49260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The balance between malignant tumor cells and the connective tissue surrounding them determines the aggressiveness of the tumor. We aimed to understand the effects of mesothelin (MSLN) and fibulin1 (FBLN1) expressions on survival in pancreas ductal adenocarcinoma (PDCA), and also whether these proteins have prognostic value for PDCA.

Methods: Of 80 patients in total, 40 who underwent the Whipple procedure for diagnosed PDCA between 2009 and 2016, and 40 patients with diagnosed pancreatitis as the control group, were included in the present study. Immunohistochemically, MSLN, and FBLN1 expressions were evaluated retrospectively. We assessed the relationship between the degree of MSLN, FBLN1 expression, clinical-pathological features, and survival rates in PDCA cases.

Results: The median follow-up duration was 11.4 (3-41) months. All of the patients for MSLN and FBLN1 were immune reactive. We detected a significant difference in MSLN expression between patients with PDCA and control groups, but not in FBLN1 expression. MSLN, FBLN1 expressions were categorized as lower-higher (L/H) groupings. There was no difference in the median overall survival (OS) of patients in the MSLN groups. The L-FBLN1 group had a median OS of 18 months (95% CI: 9.51-26.48) versus 14 months (95% CI: 13.021-14.97) in the H-FBLN1 group (interconnective tissue) (p=0.035). According to Kaplan-Meier analysis, L-FBLN1 expression in the tumor microenvironment was associated with longer survival in PDCA. The FBLN1 expression in the tumor microenvironment was shown to be significantly inversely related to OS (p=0.05).

Conclusion: The FBLN1 expression, which is in the tumor microenvironment of PDCA, may serve as a prognostic biomarker.

Abstract Image

Abstract Image

胰腺导管腺癌中纤维蛋白1和间皮素的表达。
目的:恶性肿瘤细胞与其周围结缔组织之间的平衡决定了肿瘤的侵袭性。我们旨在了解间皮素(MSLN)和纤维蛋白1 (FBLN1)表达对胰腺导管腺癌(PDCA)存活的影响,以及这些蛋白是否对PDCA具有预后价值。方法:本研究共纳入80例患者,其中40例于2009 - 2016年间行Whipple手术诊断为PDCA, 40例诊断为胰腺炎的患者为对照组。回顾性评价免疫组织化学、MSLN和FBLN1的表达。我们评估了PDCA病例中MSLN程度、FBLN1表达、临床病理特征和生存率之间的关系。结果:中位随访时间为11.4(3-41)个月。所有MSLN和FBLN1患者均有免疫反应。我们检测到PDCA患者与对照组之间MSLN表达有显著差异,但FBLN1表达无显著差异。MSLN、FBLN1表达分为低-高(L/H)组。MSLN组患者的中位总生存期(OS)无差异。L-FBLN1组的中位生存期为18个月(95% CI: 9.51-26.48),而H-FBLN1组(结缔组织)的中位生存期为14个月(95% CI: 13.021-14.97) (p=0.035)。Kaplan-Meier分析显示,L-FBLN1在肿瘤微环境中的表达与PDCA患者更长的生存期相关。FBLN1在肿瘤微环境中的表达与OS呈显著负相关(p=0.05)。结论:FBLN1在PDCA肿瘤微环境中的表达可作为预后的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Northern Clinics of Istanbul
Northern Clinics of Istanbul MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
0.00%
发文量
48
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信